Author(s)
Girolomoni G1, Gadkari A2, Auziere S3, Puig L4, Barbarot S5, Chosidow O6, de Bruin-Weller M7, Papp K8, Pink A9, Saba G3, Werfel T10, Eckert L11
1Università di Verona, Verona, Italy, 2Regeneron, Tarrytown, NY, USA, 3Kantar Health, Paris, France, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Centre Hospitalier Universitaire de Nantes, Nantes, France, 6AP-HP, Hospital Henri Mondor and EA 7379, Tassigny, France, 7University Medical Center, Utrecht, The Netherlands, 8Probity Medical Research, Waterloo, ON, Canada, 9St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and Kings College London, London, UK, 10Hannover Medical University, Hannover, Germany, 11Sanofi, Chilly-Mazarin, France
OBJECTIVES: To compare the patient-reported burden associated with atopic dermatitis (AD) across severity levels in adults in Canada and Europe. METHODS: This cross-sectional study from clinical practices included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners, or allergologists. Subjects who provided informed consent were categorized as mild (n= 369; 37.1%), moderate (n=346; 34.8%), or severe (n=277; 27.9%) AD based on Investigator’s Global Assessment, and completed a questionnaire that evaluated itch (pruritus numerical rating scale [NRS], PO-SCORAD visual analog scale [VAS]), pain NRS, sleep (PO-SCORAD VAS); quality-of-life (QoL; Dermatology Life Quality Index [DLQI]); and anxiety/depression (Hospital Anxiety and Depression Scale [HADS]). Subjects were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine (Post-cyclo; n=33 [2 mild, 11 moderate, 20 severe]) and any systemic immunomodulatory agent (Post-IMM; n=57 [8 mild, 17 moderate, 32 severe]) and compared with the severe group. RESULTS: Demographics were similar across severity groups (38.5%–47.7% male; mean age 36.6–38.4 years), but Post-cyclo and Post-IMM populations were significantly older, 44.8 and 43.5 years, respectively (P<0.05). Compared with moderate and mild AD, subjects with severe AD had significantly more comorbid atopic conditions (P<0.001); greater itch severity as indicated by significantly higher mean pruritus NRS and PO-SCORAD itch VAS scores (P<0.001); worse sleep (P<0.001 on PO-SCORAD sleep VAS); more pain (P<0.001 on pain NRS); and higher levels of anxiety and depression (P<0.001 on HADS subscales). Mean±SD DLQI score among severe patients (16.4±6.8) was consistent with a very large effect on QoL and was significantly higher than moderate (10.6±6.3; P<0.001) and mild (5.4±5.0; P<0.001). The burden among Post-cyclo and Post-IMM subjects was generally similar to that of subjects with severe AD. CONCLUSIONS: Adults with AD reported a substantial burden across multiple domains that appeared to be significantly higher in those with severe disease and in Post-cyclo/Post-IMM subjects.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSS34
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Sensory System Disorders
